20615-18-3

Usage

Uses

Used in Pharmaceutical Production:
4,4-Dimethylcyclohexylamine is used as an intermediate in the synthesis of various pharmaceuticals. Its ability to accept protons and act as a catalyst makes it a valuable component in the development of new drugs.
Used in Pesticide Production:
In the agricultural industry, 4,4-Dimethylcyclohexylamine is employed as a key intermediate in the production of certain pesticides. Its chemical properties contribute to the effectiveness of these products in controlling pests and diseases.
Used in Rubber Manufacturing:
4,4-Dimethylcyclohexylamine is used as an additive in the manufacturing of rubber. Its presence can influence the properties of the rubber, such as its flexibility and durability, making it a useful component in the production of various rubber goods.
Used in Resin and Polymer Production:
4,4-DIMETHYLCYCLOHEXYLAMINE is also utilized as an intermediate in the production of resins and polymers. Its role in these processes can affect the final properties of the materials, such as their strength, flexibility, and resistance to various environmental factors.
Safety Considerations:

InChI:InChI=1/C8H17N/c1-8(2)5-3-7(9)4-6-8/h7H,3-6,9H2,1-2H3

Upstream product

• 4701-96-6 4,4-dimethylcyclohexan-1-one oxime 
• 4255-62-3 4,4-dimethylcyclohexane-1-one 

Downstream Products

• 18192-83-1 C₂₅H₃₂FN₃O₅S 
• 18192-84-2 C₂₆H₃₄FN₃O₅S 
• 33021-79-3 N-<2-Fluor-aethyl>-N'-<4,4-dimethyl-cyclohexyl>-harnstoff 
• 18192-91-1 C₂₅H₃₃N₃O₄S 
• 18289-05-9 C₂₆H₃₅N₃O₆S 
• 18289-06-0 C₂₈H₃₇N₃O₆S 
• 137795-72-3 (R)-4-Benzyloxycarbonylamino-4-(4,4-dimethyl-cyclohexylcarbamoyl)-butyric acid benzyl ester 
• 137795-86-9 CR₂₃₆₁ 
• 137795-32-5 (R)-4-(3-Chloro-benzoylamino)-4-(4,4-dimethyl-cyclohexylcarbamoyl)-butyric acid 
• 934765-63-6 1,1-dimethylethyl({4-[(5-amino-2-fluoro-4-nitrophenyl)oxy]phenyl}methyl)(4,4-dimethylcyclohexyl)carbamate 
• 1028903-34-5 C₂₂H₂₆N₂O₃ 
• 1007579-20-5 5-bromo-N-(4,4-dimethylcyclohexyl)-2,3-dihydro-1H-inden-1-amine 
• 1007575-92-9 4′-{[(4,4-dimethylcyclohexyl)amino]methyl}-3-biphenylcarboxamide hydrochloride 
• 1473450-60-0 NITD-304 

Relevant academic research and scientific papers

Discovery and Optimization of a Compound Series Active against Trypanosoma cruzi, the Causative Agent of Chagas Disease

Chagas disease is caused by the protozoan parasite Trypanosoma cruzi. It is endemic in South and Central America and recently has been found in other parts of the world, due to migration of chronically infected patients. The current treatment for Chagas disease is not satisfactory, and there is a need for new treatments. In this work, we describe the optimization of a hit compound resulting from the phenotypic screen of a library of compounds against T. cruzi. The compound series was optimized to the level where it had satisfactory pharmacokinetics to allow an efficacy study in a mouse model of Chagas disease. We were able to demonstrate efficacy in this model, although further work is required to improve the potency and selectivity of this series.

Heterogeneous Catalytic Reductive Amination of Carbonyl Compounds with Ni-Al Alloy in Water as Solvent and Hydrogen Source

The heterogeneous catalytic reductive amination of carbonyl compounds has been achieved by reactions of ammonium hydroxide and various amines with ketones and aldehydes. The process is based on the application of Raney type Ni-Al alloy in an aqueous medium. The reaction of the carbonyl compounds with the amine provided the corresponding Schiff bases that immediately underwent a reduction to provide primary and secondary amines as products. The controlled reaction of the Al content of the alloy with the solvent water generates hydrogen, and the in situ formed Raney Ni serves as a hydrogenation catalyst. The method is a simple and efficient way of preparing a broad variety of primary and secondary amines.

INDOLE CARBOXAMIDE DERIVATIVES AND USES THEREOF

A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: (I) wherein R1, R2, R3, R4, R5 and R6 are as defined herein.

HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE

The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.